Cargando…

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

BACKGROUND: Prostate cancer (PCa), a leading cause of cancer death in North American men, displays a broad range of clinical outcome from relatively indolent to lethal metastatic disease. Several genomic alterations have been identified in PCa which may serve as predictors of progression. PTEN, (10q...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choucair, Khalil, Ejdelman, Joshua, Brimo, Fadi, Aprikian, Armen, Chevalier, Simone, Lapointe, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527151/ https://www.ncbi.nlm.nih.gov/pubmed/23171135 http://dx.doi.org/10.1186/1471-2407-12-543

Ejemplares similares

Improving ultrasound-based prostate volume estimation
por: Aprikian, Saro, et al.
Publicado: (2019)

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer
por: Audet-Walsh, Étienne, et al.
Publicado: (2017)

Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening
por: Zakaria, Ahmed S., et al.
Publicado: (2018)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
por: Derderian, Seta, et al.
Publicado: (2023)

Asporin is a stromally expressed marker associated with prostate cancer progression
por: Rochette, Annie, et al.
Publicado: (2017)

Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers
por: Chan, Sam W., et al.
Publicado: (2013)

Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study
por: Abourbih, Samuel, et al.
Publicado: (2013)

Clinical Management and Burden of Prostate Cancer: A Markov Monte Carlo Model
por: Sanyal, Chiranjeev, et al.
Publicado: (2014)

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study
por: Florianova, Livia, et al.
Publicado: (2015)

Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor
por: Luz, Murilo A, et al.
Publicado: (2010)

Broccoli, PTEN deletion and prostate cancer: where is the link?
por: Appendino, Giovanni, et al.
Publicado: (2010)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers
por: Luebke, Andreas M., et al.
Publicado: (2019)

The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases
por: Chevalier, Simone, et al.
Publicado: (2015)

Simultaneous Quantification of Mitochondrial DNA Damage and Copy Number in Circulating Blood: A Sensitive Approach to Systemic Oxidative Stress
por: Chan, Sam W., et al.
Publicado: (2013)

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
por: Bachir, Bassel G., et al.
Publicado: (2017)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
por: Ouellet, Véronique, et al.
Publicado: (2018)

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer
por: Chauhan, Gaurav, et al.
Publicado: (2021)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer
por: de Nóbrega, Monyse, et al.
Publicado: (2020)

Transcriptional landscape of PTEN loss in primary prostate cancer
por: Imada, Eddie Luidy, et al.
Publicado: (2021)

Liquid biopsy‐based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer
por: Derderian, Seta, et al.
Publicado: (2022)

Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer
por: Rouleau, Michèle, et al.
Publicado: (2022)

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?
por: Poluri, Raghavendra Tejo Karthik, et al.
Publicado: (2018)

PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo
por: Parisotto, Maxime, et al.
Publicado: (2018)

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
por: Jacobsen, Frank, et al.
Publicado: (2017)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer
por: Vidotto, Thiago, et al.
Publicado: (2018)

Conditional Deletion of the Pten Gene in the Mouse Prostate Induces Prostatic Intraepithelial Neoplasms at Early Ages but a Slow Progression to Prostate Tumors
por: Kwak, Mi Kyung, et al.
Publicado: (2013)

Klf5 Deletion Promotes Pten Deletion–Initiated Luminal-Type Mouse Prostate Tumors through Multiple Oncogenic Signaling Pathways()()
por: Xing, Changsheng, et al.
Publicado: (2014)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
por: Hu, Jason, et al.
Publicado: (2022)

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
por: Yoshimoto, M, et al.
Publicado: (2007)

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression
por: Li, Yingming, et al.
Publicado: (2012)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels
por: Crespo-Masip, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gcr032e87hg9amfs763ci03m3s